Emily Cooper, Mark Wright, and Andrea Taylor break down three breaking metabolic health stories in this quick bonus episode from a newly approved oral GLP-1 to a major price drop for Medicare patients
Programs that can offer both, along with oral and injectable formats, give patients more room to find what actually works for their body
The EY-Parthenon analysis shows a potential reduction in sales of as much as 3% across the salty, sweet and confectionary snack categories, likely impeding growth opportunities for manufacturers
The dosage is typically initiated at a low level and titrated upward over a multi-week clinical cycle
Among participants on tirzepatide, the rate of new-onset type 2 diabetes was dramatically lower: 0.4% for the 15 mg group compared to 13.3% for placebo over three years
In head-to-head trials, tirzepatide's dual-receptor mechanism (GLP-1 plus GIP) tended to produce larger average weight loss than semaglutide, which targets GLP-1 alone